histrelin and Gender-Dysphoria

histrelin has been researched along with Gender-Dysphoria* in 3 studies

Other Studies

3 other study(ies) available for histrelin and Gender-Dysphoria

ArticleYear
Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation.
    Journal of pediatric endocrinology & metabolism : JPEM, 2021, Nov-25, Volume: 34, Issue:11

    The purpose of this study was to review our success rate performing the histrelin implant procedure in clinic without sedation.. A retrospective study was performed for histrelin implant procedures done at our institution from 2008 to 2020. Wilcoxon rank-sum test or Fisher's exact test was utilized to identify significant differences (p<0.05).. A total of 73 patients underwent 184 histrelin implant procedures from 2008 to 2020. In the past few years, there has been a decrease in procedures for precocious puberty and an increase for gender dysphoria. The majority of procedures were performed in clinic without sedation (82%). The only risk factor associated with requiring sedation was younger age (median 9 vs. 10 years; p<0.003). Complications (i.e. implant fracture or need for counter-incision) were noted in 10 of the procedures (5%). The only risk factor identified for a procedural complication during implant removal/replacement was interval time from insertion (21 vs. 13 months; p<0.01). The only documented wound problem reported was dermatitis in 1 patient (no suture granuloma, dehiscence, or implant extravasation).. Procedural refinements and distraction therapy have enabled us to perform the majority of procedures in clinic without sedation. In our experience, procedural difficulty and complications appear to increase with prolonged implant duration. Histrelin implantation is increasingly being performed for gender dysphoria.

    Topics: Adolescent; Child; Child, Preschool; Drug Implants; Female; Gender Dysphoria; Gonadotropin-Releasing Hormone; Humans; Male; Puberty, Precocious; Retrospective Studies; Risk Factors; Treatment Outcome

2021
Histrelin implantation in the pediatric population: A 10-year institutional experience.
    Journal of pediatric surgery, 2019, Volume: 54, Issue:7

    To perform the largest review of the safety and clinical management practices of histrelin implantation in children.. A retrospective cohort study was performed including all patients (age ≤ 20) that underwent histrelin implant insertion, replacement, or removal by a single surgeon at a large pediatric tertiary care center (2008-2017). Data analyzed included patient demographics, procedure details, and complications.. A total of 377 patients, with a mean age of 9.3 ± 2.4 years, underwent 866 unique procedures (352 insertions, 329 replacements, and 185 removals) for a diagnosis of either central precocious puberty (343 patients, 821 cases) or gender identity disorder (34 patients, 45 cases). There were 271 (72%) female patients, 72 (19%) male patients, and 34 (9%) children in gender transition. Procedures were performed in three settings: 415 (47.9%) in the outpatient clinic, 401 (46.3%) in a sedation unit, and 50 (5.8%) in the operating room. The preferred setting shifted over time to more clinic-based procedures (9.4% vs. 62.9% in the first five vs. second five years, respectively). Complications were rare (1% of cases).. Histrelin implantation in the pediatric population is safe, with minimal morbidity. Implantation and removal in the clinic setting are appropriate for the majority of patients.. Treatment study; Level IV.

    Topics: Ambulatory Care Facilities; Child; Drug Implants; Female; Gender Dysphoria; Gender Identity; Gonadotropin-Releasing Hormone; Humans; Male; Operating Rooms; Puberty, Precocious; Retrospective Studies

2019
Trends in the use of puberty blockers among transgender children in the United States.
    Journal of pediatric endocrinology & metabolism : JPEM, 2018, Jun-27, Volume: 31, Issue:6

    The objective of the study was to identify national trends in the utilization of histrelin acetate implants among transgender children in the United States.. We analyzed demographic, diagnostic and treatment data from 2004 to 2016 on the use of histrelin acetate reported to the Pediatric Health Information System (PHIS) to determine the temporal trends in its use for transgender-related billing diagnoses, e.g. "gender identity disorder". Demographic and payer status data on this patient population were also collected.. Between 2004 and 2016, the annual number of implants placed for a transgender-related diagnosis increased from 0 to 63. The average age for placement was 14 years. Compared to natal females, natal males were more likely to receive implants (57 vs. 46) and more likely to have implants placed at an older age (62% of natal males vs. 50% of natal females were ≥;13 years; p<0.04). The majority of children were White non-Hispanic (White: 60, minority: 21). When compared to the distribution of patients treated for precocious puberty (White: 1428, minority: 1421), White non-Hispanic patients were more likely to be treated with a histrelin acetate implant for a transgender-related diagnosis than minority patients (p<0.001). This disparity was present even among minority patients with commercial insurance (p<0.001).. Utilization of histrelin acetate implants among transgender children has increased dramatically. Compared to natal females, natal males are more likely to receive implants and also more likely to receive implants at an older age. Treated transgender patients are more likely to be White when compared to the larger cohort of patients being treated with histrelin acetate for central precocious puberty (CPP), thus identifying a potential racial disparity in access to medically appropriate transgender care.

    Topics: Adolescent; Child; Child, Preschool; Drug Implants; Female; Gender Dysphoria; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Infant; Male; Puberty; Puberty, Delayed; Puberty, Precocious; Retrospective Studies; Transgender Persons; United States

2018